Testifying methylomics blood test for new kidney cancer monitoring
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed kidney cancer
- You have not received any cancer treatment yet
- You plan to have curative (radical) surgery as your treatment
- Your usual day-to-day ability is good (ECOG score 0–1)
- You can follow the study’s follow-up visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This study looks for “biomarkers,” which are measurable signs (often from blood or tissue), to better understand kidney cancer. It may help doctors identify who has kidney cancer and how it behaves.
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
This study uses an at-home-style urine test (urine “omics,” meaning detailed lab information) to help predict how well immunotherapy may work for advanced kidney cancer. If you join, your urine results may help doctors tailor treatment choices and better understand who benefits most.
This trial checks whether a CpG-methylation test can help sort people with stage III clear cell kidney cancer who are planning adjuvant (after-surgery) treatment. It may help doctors choose the most appropriate follow-up plan based on your cancer’s risk pattern.
This study looks at whether a simple blood test can detect tiny bits of kidney cancer DNA after surgery. If successful, it could help doctors spot a return of cancer earlier than scans alone.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.